3 Key Takeaways
Plain English Summary- 01Core Finding
Here we report the results of a Phase 1 clinical trial testing the feasibility and safety of personalized tumor-specific protein flag (neoantigen)-targeting cancer vaccines for high-grade epithelial ovarian cancer.
- 02Study Evidence
Tested in a early human trial + observational cohort study at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
What This Means for You
biomarker (measurable biological signal) analysis was suggestive of biologic activity of the vaccine in six of ten patients and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination. Resistant tumor clones reflected diverse mechanisms affecting antigen presentation, indicative of immune-selective pressure exerted by vaccination.
Overall, the interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy (real-world effectiveness in the trial) following vaccination. .
The Discovery
Personalized tumor-specific protein flag (neoantigen)-targeting cancer vaccines in the adjuvant setting are of increasing interest across malignancies. Here we report the results of a Phase 1 clinical trial testing the feasibility and safety of personalized neoantigen-targeting cancer vaccines for high-grade epithelial ovarian cancer. 'NeoVax' consisted of pools of synthetic long peptides targeting patient-specific neoantigens admixed with the immunostimulant poly-ICLC, was combined with delayed administration of anti-PD-1 antibody, and was tested in ten patients (one newly diagnosed patient (Cohort A) and nine patients at first recurrence (Cohort B)) with platinum-sensitive ovarian cancer following standard-of-care platinum doublet chemotherapy. Nine of 12 evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%) and 1 of 9 Cohort A patients (11%, 90% CI 0.6-43%). No unexpected safety signals were encountered and no patients discontinued treatment due to toxicity. Across patients, >70% selected targets remained detectable by noninvasive cell-free DNA analysis despite a median of 6.5 months from the time of diagnostic biopsy to vaccine administration, during which, patients received standard-of-care chemotherapy.
How It Works, Simply
This oncology research focuses on antibodies · Immune response · Blood biomarker (measurable biological signal). Researchers evaluated it using an early human trial + Observational cohort study at the Phase I/II stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Here we report the results of a Phase 1 clinical trial testing the feasibility and safety of personalized neoantigen-targeting cancer vaccines for high-grade epithelial ovarian cancer.
- 02Study Evidence
Tested in a early human trial + observational cohort study at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
Biological Mechanism & Study Design
Study Design & Cohort
Early human trial + Observational cohort study
Early human trial + Observational cohort study · Phase I/II
Biological Pathway & Modality
Antibodies · Immune response · Blood biomarker
Intervention: Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial
Experimental Findings & Endpoints
Personalized neoantigen-targeting cancer vaccines in the adjuvant setting are of increasing interest across malignancies.
Here we report the results of a Phase 1 clinical trial testing the feasibility and safety of personalized neoantigen-targeting cancer vaccines for high-grade epithelial ovarian cancer. 'NeoVax' consisted of pools of synthetic long peptides targeting patient-specific neoantigens admixed with the immunostimulant poly-ICLC, was combined with delayed administration of anti-PD-1 antibody, and was tested in ten patients (one newly diagnosed patient (Cohort A) and nine patients at first recurrence (Cohort B)) with platinum-sensitive ovarian cancer following standard-of-care platinum doublet chemotherapy.
Nine of 12 evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%) and 1 of 9 Cohort A patients (11%, 90% CI 0.6-43%). No unexpected safety signals were encountered and no patients discontinued treatment due to toxicity.
Across patients, >70% selected targets remained detectable by noninvasive cell-free DNA analysis despite a median of 6.5 months from the time of diagnostic biopsy to vaccine administration, during which, patients received standard-of-care chemotherapy.
Clinical Translation & Practice Context
Biomarker analysis was suggestive of biologic activity of the vaccine in six of ten patients and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination.
Resistant tumor clones reflected diverse mechanisms affecting antigen presentation, indicative of immune-selective pressure exerted by vaccination.
Overall, the interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination. .
The Bottom Line · Clinical Pearl
“Overall, the interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination. .”
Published in Nature Medicine · Current Stage: Phase I/II